Clinical trials
Atopic Dermatitis clinical trials
Below are recruiting atopic dermatitis clinical trials, each written for real people, not researchers. We’re tracking 175 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06947980RecruitingPhase 2
Study of CM512 for moderate-to-severe atopic dermatitis
This trial tests a new treatment called CM512 for people with moderate-to-severe eczema (atopic dermatitis). It aims to see if the drug can improve skin symptoms like itching and rash.
BeijingAges 18–75 - NCT06947993RecruitingPhase 2
Study of a new treatment for moderate to severe eczema
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
Birmingham, AlabamaAges 18–100 - NCT06931990RecruitingPhase 1/Phase 2
Testing a new tablet for eczema in Chinese adults
This trial tests an experimental tablet (LT-002-158) for adults with moderate-to-severe eczema that hasn't improved enough with standard creams. The goal is to see if the tablet is safe and helps control symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT06899204Recruiting
Abrocitinib for atopic dermatitis after biologic therapy
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
San Diego, CaliforniaAges 12 years+ - NCT06880276RecruitingPhase 3
Studying QLM3003 ointment for mild or moderate eczema
This trial tests if an ointment called QLM3003 is safe and helps adults with mild to moderate atopic dermatitis (eczema). It may be a new treatment option for people whose eczema affects small areas of skin.
ShenyangAges 18–75 - NCT06855745RecruitingPhase 2
Testing a new gel for mild to moderate eczema
This study tests a new gel called Zabalafin Hydrogel to see if it helps people with mild to moderate atopic dermatitis (eczema). The gel is applied directly to the skin. If you or your child has eczema on the head, neck, trunk, or limbs, this trial may be an option.
Brookvale, New South WalesAges 2 years+ - NCT06775860RecruitingPhase 3
Testing ICP-332 for moderate to severe eczema
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hefei, AnhuiAges 18–75 - NCT06464133Enrolling by invitation
Filaggrin gene study in Latinx patients with eczema
This study looks for gene changes (filaggrin mutations) in Latinx/Hispanic patients with atopic dermatitis (eczema) to better understand how these genes affect the condition. It involves a simple skin test or saliva sample.
Philadelphia, PennsylvaniaAges Any age - NCT06397911RecruitingPhase 2
Testing FB825 for moderate to severe eczema
This trial tests a new injectable medicine called FB825 for people with moderate to severe eczema that hasn't improved enough with standard creams. The study aims to see if FB825 can reduce itching and skin symptoms safely.
Fountain Valley, CaliforniaAges 18–65 - NCT06055361RecruitingPhase 1
Studying a new injection for moderate to severe eczema
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
North Little Rock, ArkansasAges 18 years+ - NCT06311682RecruitingPhase 3
Testing a new shot plus steroid cream for children with eczema
This study tests an investigational shot (tralokinumab) plus a steroid cream for children with moderate-to-severe eczema that hasn't been controlled by creams alone. It aims to see if the combination is safe and works better than the cream alone.
Birmingham, AlabamaAges 6 months–11 years - NCT06244212Recruiting
Atopic dermatitis treatment with steroid cream trial
This trial tests a common steroid cream (triamcinolone) for atopic dermatitis (a type of eczema). It aims to see how well it works in people who have active skin inflammation and can come back for a follow-up visit one week later.
Winston-Salem, North CarolinaAges 9 years+ - NCT06004986RecruitingPhase 4
Lowering Dupilumab Dose in Controlled Eczema
This study looks at whether people with well-controlled eczema can safely lower their dose of dupilumab (an injected medication). It aims to see if a reduced dose still keeps eczema under control.
Amsterdam, North HollandAges 18 years+ - NCT06116526RecruitingPhase 4
Reducing Dupixent in kids with well-controlled eczema
This study looks at whether children with well-controlled eczema can safely reduce how often they take Dupixent. It aims to find the lowest effective dose to keep eczema under control.
Baltimore, MarylandAges 1–17 - NCT06096857RecruitingPhase 2
Cardamom and topical bacteria cream for eczema
This study tests whether taking cardamom by mouth and applying a cream made from a harmless bacteria (Roseomonas) can help treat eczema (atopic dermatitis) in people age 2 and older.
Bethesda, MarylandAges 2–100 - NCT05995964RecruitingPhase 2
Study of two new medicines for eczema
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Birmingham, AlabamaAges 18 years+ - NCT05735483Enrolling by invitationPhase 3
Long-term lebrikizumab study for moderate to severe eczema
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
Birmingham, AlabamaAges 6 months–18 years - NCT05689151Recruiting
Abrocitinib for adult moderate to severe atopic eczema
This study tests how well abrocitinib (a prescription medicine) works for adults with moderate to severe atopic dermatitis (atopic eczema). You may join if you meet the study’s health and consent requirements and your doctor believes abrocitinib is an appropriate option for you.
Amiens, SommeAges 18 years+ - NCT05391061Recruiting
Cibinqo tablet study for moderate-to-severe atopic dermatitis
This study looks at Cibinqo (an oral medicine) in people with moderate-to-severe atopic dermatitis (eczema) who are already going to start it under their clinician’s standard care plan. It may help doctors learn about how the medicine works and fits into real-world treatment.
SeoulAges 12 years+ - NCT04826744Recruiting
Atopic dermatitis study tracking eyelid involvement
This study looks at how often the eyelids are affected in adults with atopic dermatitis (a long-term skin condition). It may help doctors better understand patterns of skin and eyelid symptoms so care can be improved.
LilleAges 18 years+ - NCT05042258RecruitingPhase 4
Dupilumab to improve sleep and itch in children with eczema
This trial studies whether dupilumab can improve daily body clock (circadian function), sleep, and itching in children with moderate-to-severe eczema that isn’t well controlled by creams. It may help kids who are having significant sleep trouble and ongoing itch.
Chicago, IllinoisAges 6–17 - NCT04240522Recruiting
Long-term study of eczema and related allergies
This observational study follows people with eczema (atopic dermatitis) and sometimes related allergies over time, even if they keep their usual medical treatments. It may help researchers better understand how these conditions change and what factors relate to symptoms.
Zurich, Canton of ZurichAges 1–85 - NCT04170244Recruiting
Skin microbiome study in atopic dermatitis and psoriasis
This study looks at the skin’s germs (“microbiome”) in people with atopic dermatitis (eczema) or psoriasis. It may help researchers better understand what’s going on on the skin and how that might relate to disease severity.
Rochester, New YorkAges 13 years+ - NCT01631617RecruitingPhase 2
Atopic dermatitis treatments and how they affect skin
This Phase 2 study tests different treatments for atopic dermatitis (eczema) by looking at changes in skin health. It may help people find safer, more effective ways to control moderate to severe eczema and related skin infections.
Bethesda, MarylandAges 2–50
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atopic dermatitis?
- Yes. Clin2 currently lists 175 recruiting atopic dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atopic dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.